Dyspepsia Clinical Trial
Official title:
Evaluating Changes in Quality of Life and Digestion in Functional Dyspepsia in Adults
The purpose of this study is to determine the effects of a readily available dietary supplement on quality of life and digestion in adults with functional dyspepsia.
Status | Recruiting |
Enrollment | 64 |
Est. completion date | December 31, 2024 |
Est. primary completion date | June 1, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - ? Adults 18-70 years of age (inclusive) - A self-reported history of symptoms consistent with Functional Dyspepsia (per Rome IV criteria - See Telephone Screening), and self-reported absence of organic disease and infection (e.g., Helicobacter pylori) with or without a formal diagnosis by a healthcare professional. - Adults = 60 years of age must have had a normal upper gastrointestinal endoscopy - Willing to be randomized to take a daily dietary supplement or placebo over the 4-week study period - Not taken antibiotics or other drugs prescribed specifically for symptoms consistent with Functional Dyspepsia (per Rome IV criteria) for a period up to 1 month before the beginning of the study. - On a stable dose of all medications prior to study entry (i.e., consistent dose for a minimum of three months) - On a stable dose of dietary supplements for at least one month prior to enrollment - Willing to avoid initiation of new supplements and/or medications unless otherwise indicated by a healthcare professional - Able to communicate via email, complete computer-administered questionnaires, and to read and write in English. - Approved to be eligible for study participation at the discretion of the Principal Investigators, after review of the Formal Eligibility Screen results. - Non-smokers (including tobacco and cannabis products, combusted or vaporized) - Willing to provide written informed consent and to follow the required protocol Exclusion Criteria: - ? A self-reported history of peptic and/or duodenal ulcers, H. pylori infection, gastroesophageal reflux disease (GERD) explained by upper endoscopy, irritable bowel syndrome (IBS), and other chronic GI disorders. - Positive fecal occult blood test (FOBT) at the clinical screening visit - Current use of digestive enzyme and/or betaine HCL-containing dietary supplements - Current use of prescribed proton-pump inhibitors - Current use of drugs that interfere with gastrointestinal motility, including prokinetic agents. - History of previous abdominal surgery, including gastric surgery, excluding appendectomy. - Individuals with chronic kidney or liver disease, cancer, colorectal disease and/or other rare disorders that at the discretion of the PI or Clinical Investigator may impact their safety or confound trial results - Current involvement or within 14 days prior to screening of a significant diet or weight loss program (such as NutriSystem, Jenny Craig, Atkin's or other low-carb diet programs) or very low-calorie liquid diet programs (such as Optifast, Medifast, and/or HMR) - Hospitalization (for any reason other than a scheduled medical procedure unrelated to Functional Dyspepsia) within 3 months prior to screening - Malignancy within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix) - Intake of = 2 standardized alcohol-containing beverages per day, 14 per week, or =4 in any single day within the past 14 days. - Individuals who do not consume, or are allergic to, animal products - Smoking tobacco or nicotine products (combusted or vaporized) - Use of illicit drugs/substances (such as but not limited to cocaine, phencyclidine (PCP), and methamphetamine) within 14 days of screening - Currently participating in another interventional research study, or participated in another interventional research study within 14 days of screening |
Country | Name | City | State |
---|---|---|---|
United States | Helfgott Research Institute | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
National University of Natural Medicine |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Microbiota Relative Abundance and Composition | Objective measure of amount and types of gut microbes | Baseline | |
Other | Microbiota Relative Abundance and Composition | Objective measure of microbiota abundance, composition, diversity | Week 4 | |
Other | Blood glucose | Blood concentrations of glucose | Baseline | |
Other | Blood glucose | Blood concentrations of glucose | Week 4 | |
Other | Urea Nitrogen | Blood concentrations of Urea Nitrogen | Baseline | |
Other | Urea Nitrogen | Blood concentrations of Urea Nitrogen | Week 4 | |
Other | Creatinine | Blood concentrations of creatinine | Baseline | |
Other | Creatinine | Blood concentrations of creatinine | Week 4 | |
Other | Urea Nitrogen to creatinine ratio | ratio of blood concentrations of urea nitrogen to creatinine | baseline | |
Other | Urea Nitrogen to creatinine ratio | ratio of blood concentrations of urea nitrogen to creatinine | Week 4 | |
Other | Sodium | blood concentrations of Sodium | Baseline | |
Other | Sodium | blood concentrations of Sodium | Week 4 | |
Other | Potassium | blood concentrations of Potassium | Baseline | |
Other | Potassium | blood concentrations of Potassium | Week 4 | |
Other | Chloride | blood concentrations of Chloride | Baseline | |
Other | Chloride | blood concentrations of Chloride | Week 4 | |
Other | Carbon Dioxide | blood concentration of carbon dioxide | baseline | |
Other | Carbon Dioxide | blood concentration of carbon dioxide | week 4 | |
Other | Calcium | blood concentration of calcium | Baseline | |
Other | Calcium | blood concentration of calcium | Week 4 | |
Other | Total Protein | Total protein in blood | Baseline | |
Other | Total Protein | Total protein in blood | Week 4 | |
Other | Albumin | Concentration of albumin in blood | Baseline | |
Other | Albumin | Concentration of albumin in blood | Week 4 | |
Other | Globulin | Concentration of globulin in blood | baseline | |
Other | Globulin | Concentration of globulin in blood | Week 4 | |
Other | Albumin to Globulin ratio | Ratio of the blood concentrations of albumin to globulin | Baseline | |
Other | Albumin to Globulin ratio | Ratio of the blood concentrations of albumin to globulin | Week 4 | |
Other | Bilirubin | Concentrations of bilirubin in blood | baseline | |
Other | Bilirubin | Concentrations of bilirubin in blood | Week 4 | |
Other | Alkaline Phosphatase | Concentrations of alkaline phosphatase in blood | baseline | |
Other | Alkaline Phosphatase | Concentrations of alkaline phosphatase in blood | Week 4 | |
Other | aspartate aminotransferase | Concentrations of aspartate aminotransferase in blood | Baseline | |
Other | aspartate aminotransferase | Concentrations of aspartate aminotransferase in blood | Week 4 | |
Other | Alanine aminotransferase | Concentrations of Alanine aminotransferase in blood | baseline | |
Other | Alanine aminotransferase | Concentrations of Alanine aminotransferase in blood | Week 4 | |
Other | Estimated glomerular filtration rate | glomerular filtration rate per 1.73 sqM estimated | baseline | |
Other | Estimated glomerular filtration rate | glomerular filtration rate per 1.73 sqM estimated | Week 4 | |
Other | White blood cell count | Amount of leukocytes in blood | baseline | |
Other | White blood cell count | Amount of leukocytes in blood | Week 4 | |
Other | Red blood cell count | Amount of erythrocytes in blood | baseline | |
Other | Red blood cell count | Amount of erythrocytes in blood | Week 4 | |
Other | Hemoglobin | Amount of hemoglobin in blood | baseline | |
Other | Hemoglobin | Amount of hemoglobin in blood | Week 4 | |
Other | Hematocrit | Amount of hematocrit in blood | baseline | |
Other | Hematocrit | Amount of hematocrit in blood | Week 4 | |
Other | Mean corpuscular volume | Mean corpuscular volume of erythrocytes | baseline | |
Other | Mean corpuscular volume | Mean corpuscular volume of erythrocytes | Week 4 | |
Other | Mean corpuscular hemoglobin | Mean corpuscular hemoglobin of erythrocytes | baseline | |
Other | Mean corpuscular hemoglobin | Mean corpuscular hemoglobin of erythrocytes | Week 4 | |
Other | Mean corpuscular hemoglobin concentration | Mean corpuscular hemoglobin concentration of erythrocytes | baseline | |
Other | Mean corpuscular hemoglobin concentration | Mean corpuscular hemoglobin concentration of erythrocytes | Week 4 | |
Other | Erythrocyte distribution width | Erythrocyte distribution width | baseline | |
Other | Erythrocyte distribution width | Erythrocyte distribution width | Week 4 | |
Other | Platelet count | amount of platelets in blood | baseline | |
Other | Platelet count | amount of platelets in blood | Week 4 | |
Other | Neutrophils | amount of neutrophils in blood | baseline | |
Other | Neutrophils | amount of neutrophils in blood | Week 4 | |
Other | Band Neutrophils | Neutrophils band form per 100 leukocytes | baseline | |
Other | Band Neutrophils | Neutrophils band form per 100 leukocytes | Week 4 | |
Other | Absolute band neutrophils | Amount of Neutrophils band form | baseline | |
Other | Absolute band neutrophils | Amount of Neutrophils band form | Week 4 | |
Other | Metamyelocytes | Amount of metamyelocytes per 100 leukocytes | baseline | |
Other | Metamyelocytes | Amount of metamyelocytes per 100 leukocytes | Week 4 | |
Other | Absolute Metamyelocytes | Amount of metamyelocytes | baseline | |
Other | Absolute Metamyelocytes | Amount of metamyelocytes | Week 4 | |
Other | Myelocytes | Amount of metamyelocytes per 100 leukocytes | baseline | |
Other | Myelocytes | Amount of metamyelocytes per 100 leukocytes | Week 4 | |
Other | Absolute Myelocytes | Amount of myelocytes | baseline | |
Other | Absolute Myelocytes | Amount of myelocytes | Week 4 | |
Other | Promyelocytes | Amount of promyelocytes per 100 leukocytes | baseline | |
Other | Promyelocytes | Amount of promyelocytes per 100 leukocytes | Week 4 | |
Other | Absolute Promyelocytes | Amount of promyelocytes | baseline | |
Other | Absolute Promyelocytes | Amount of promyelocytes | Week 4 | |
Other | Absolute Neutrophils | Amount of neutrophils in blood | baseline | |
Other | Absolute Neutrophils | Amount of neutrophils in blood | Week 4 | |
Other | Lymphocytes | Amount of lymphocytes in blood per 100 leukocytes | baseline | |
Other | Lymphocytes | Amount of lymphocytes in blood per 100 leukocytes | Week 4 | |
Other | Reactive Lymphocytes | Amount of reactive lymphocytes in blood per 100 leukocytes | baseline | |
Other | Reactive Lymphocytes | Amount of reactive lymphocytes in blood per 100 leukocytes | Week 4 | |
Other | Absolute Lymphocytes | Amount of reactive lymphocytes in blood | baseline | |
Other | Absolute Lymphocytes | Amount of reactive lymphocytes in blood | Week 4 | |
Other | Monocytes | Amount of monocytes in blood per 100 leukocytes | baseline | |
Other | Monocytes | Amount of monocytes in blood per 100 leukocytes | Week 4 | |
Other | Absolute monocytes | Amount of monocytes in blood | baseline | |
Other | Absolute monocytes | Amount of monocytes in blood | Week 4 | |
Other | Eosinophils | Amount of eosinophils in blood per 100 leukocytes | baseline | |
Other | Eosinophils | Amount of eosinophils in blood per 100 leukocytes | Week 4 | |
Other | Absolute Eosinophils | Amount of eosinophils in blood | baseline | |
Other | Absolute Eosinophils | Amount of eosinophils in blood | Week 4 | |
Other | Basophils | Amount of basophils in blood per 100 leukocytes | baseline | |
Other | Basophils | Amount of basophils in blood per 100 leukocytes | Week 4 | |
Other | Absolute Basophils | Amount of basophils in blood | baseline | |
Other | Absolute Basophils | Amount of basophils in blood | Week 4 | |
Other | Blasts | Amount of blasts in blood per 100 leukocytes | baseline | |
Other | Blasts | Amount of blasts in blood per 100 leukocytes | Week 4 | |
Other | Absolute Blasts | Amount of blasts in blood | baseline | |
Other | Absolute Blasts | Amount of blasts in blood | Week 4 | |
Other | Nucleated red blood cells | Amount of nucleated erythrocytes per 100 leukocytes | baseline | |
Other | Absolute Nucleated red blood cells | Amount of nucleated erythrocytes in blood | baseline | |
Other | Absolute Nucleated red blood cells | Amount of nucleated erythrocytes in blood | Week 4 | |
Other | Platelet mean volume | Mean volume of platelets in blood | baseline | |
Other | Platelet mean volume | Mean volume of platelets in blood | Week 4 | |
Primary | Protein Assimilation | Concentrations of Amino Acids in Blood | Baseline | |
Primary | Protein Assimilation | Concentrations of Amino Acids in Blood | Week 4 | |
Secondary | Mineral concentrations in blood | Mineral concentrations in blood as measured by Genova Diagnostics NutrEval | Baseline | |
Secondary | Mineral concentrations in blood | Mineral concentrations in blood as measured by Genova Diagnostics NutrEval | Week 4 | |
Secondary | Fat-soluble vitamin concentration in blood | Fat-soluble vitamin concentrations in blood as measured by Genova Diagnostics NutrEval | Baseline | |
Secondary | Fat-soluble vitamins | Fat-soluble vitamin concentrations in blood as measured by Genova Diagnostics NutrEval | Week 4 | |
Secondary | Leeds Dyspepsia Questionnaire | Subjective measure of digestive symptoms | Baseline | |
Secondary | Leeds Dyspepsia Questionnaire | Subjective measure of digestive symptoms | Week 4 | |
Secondary | Patient Reported Outcomes Measurement Information System (PROMIS)-29 Physical Function Subscale | Subjective measure of Quality of life related to physical function | Baseline | |
Secondary | Patient Reported Outcomes Measurement Information System (PROMIS)-29 Physical Function Subscale | Subjective measure of Quality of life related to physical function | Week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06094062 -
Smartphone App-assisted PPI
|
N/A | |
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Completed |
NCT04429802 -
The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Withdrawn |
NCT02863822 -
Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.
|
N/A | |
Recruiting |
NCT00978159 -
Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
|
Phase 4 | |
Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00148603 -
Montelukast in the Treatment of Duodenal Eosinophilia
|
N/A | |
Terminated |
NCT00220844 -
Tricyclic Antidepressants (TCAs) on Gastric Emptying
|
N/A | |
Completed |
NCT00232102 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Completed |
NCT00110968 -
Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia
|
Phase 3 | |
Completed |
NCT00232037 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Completed |
NCT00164996 -
Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia
|
Phase 3 | |
Recruiting |
NCT05718960 -
Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia
|
N/A | |
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Completed |
NCT05750641 -
The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
|
||
Completed |
NCT03252743 -
ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.
|
N/A | |
Completed |
NCT04697641 -
Helicobacter Pylori Eradication in Functional Dyspepsia
|
N/A | |
Recruiting |
NCT04918329 -
Functional Digestive Disorders Observatory
|